Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies
Top Cited Papers
Open Access
- 24 January 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 64 (7), 2311-2318
- https://doi.org/10.1002/art.34402
Abstract
Objective To investigate which serologic and clinical findings predict adverse pregnancy outcome in patients with antiphospholipid antibody (aPL) and to test the hypothesis that a pattern of clinical and serologic variables can identify women at highest risk of adverse pregnancy outcome. Methods Women enrolled in a multicenter prospective observational study of risk factors for adverse pregnancy outcome in patients with aPL (lupus anticoagulant [LAC], anticardiolipin antibody [aCL], and/or antibody to β2‐glycoprotein I [anti‐β2GPI]) and/or systemic lupus erythematosus (SLE) were recruited for the present prospective study. Demographic, clinical, serologic, and treatment data were recorded at the time of the first study visit. The relationship between individual and combined variables and adverse pregnancy outcome was assessed by bivariate and multivariate analysis. Results Between 2003 and 2011 we enrolled 144 pregnant patients, of whom 28 had adverse pregnancy outcome. Thirty‐nine percent of the patients with LAC had adverse pregnancy outcome, compared to 3% of those who did not have LAC (P < 0.0001). Among women with IgG aCL at a level of ≥40 units/ml, only 8% of those who were LAC negative had adverse pregnancy outcome, compared to 43% of those who were LAC positive (P = 0.002). IgM aCL, IgG anti‐β2GPI, and IgM anti‐β2GPI did not predict adverse pregnancy outcome. In bivariate analysis, adverse pregnancy outcome occurred in 52% of patients with and 13% of patients without prior thrombosis (P = 0.00005), and in 23% with SLE versus 17% without SLE (not significant); SLE was a predictor in multivariate analysis. Prior pregnancy loss did not predict adverse pregnancy outcome. Simultaneous positivity for aCL, anti‐β2GPI, and LAC did not predict adverse pregnancy outcome better than did positivity for LAC alone. Conclusion LAC is the primary predictor of adverse pregnancy outcome after 12 weeks' gestation in aPL‐associated pregnancies. Anticardiolipin antibody and anti‐β2GPI, if LAC is not also present, do not predict adverse pregnancy outcome.This publication has 38 references indexed in Scilit:
- Anti-β2-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy lossFertility and Sterility, 2010
- Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcomeArthritis Care & Research, 2010
- Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-β2-glycoprotein-I antibody positivity offer additional predictive information?Lupus, 2009
- Are laboratories following published recommendations for lupus anticoagulant testing?Thrombosis and Haemostasis, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidityThrombosis and Haemostasis, 2006
- ACOG Practice Bulletin #58: Ultrasonography in PregnancyObstetrics & Gynecology, 2004
- Use of the Dilute Russell Viper Venom Time (dRVVT): Its Importance and PitfallsJournal of Autoimmunity, 2000
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Antiphospholipid antibodies and fetal deathObstetrics & Gynecology, 1996